---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269468"
form_type: "8-K"
ticker: "OKUR"
cik: "0001637715"
company_name: "OnKure Therapeutics, Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:44:11.220986+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# OnKure Q3 net loss $14.7M; cash $70.3M; initial data from PI3K trial pushed to Q1 2026

## Summary
- Cash $70.3M as of Sept 30, 2025; expected to fund operations into Q4 2026.
- Net loss $14.7M ($1.09/share) vs $11.6M loss in Q3 2024.
- First patients dosed in two triplet arms of PIKture-01: fulvestrant+ribociclib and trastuzumab+tucatinib.
- Initial clinical data from monotherapy and fulvestrant arms now expected Q1 2026.
- Next-gen PI3Kα pan-mutant inhibitor candidate selection announced; more details Q1 2026.

## SEC filing metadata
- accession: 0001193125-25-269468
- form_type: 8-K
- ticker: OKUR
- cik: 0001637715
- company_name: OnKure Therapeutics, Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1637715/000119312525269468/0001193125-25-269468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1637715/000119312525269468/okur-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269468
- JSON: https://secwatch.observer/filing/0001193125-25-269468.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269468.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.